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httpcense.Abstract 27 patients diagnosed as chronic obstructive pulmonary disease (COPD) came with acute
hypercapnic respiratory failure due to COPD and met the inclusion and exclusion criteria. They
were managed by non invasive positive pressure ventilation (NIPPV). 21 cases showed success
and 6 cases showed failure and were put on invasive mechanical ventilation within the ﬁrst 24 h.
It was shown that before initiation of NIPPV, the failed cases had signiﬁcantly higher Body Mass
Index (BMI) 34.7 compared to 28.1 in successful cases and signiﬁcantly lower pH 7.20 ± 0.05 com-
pared with 7.27 ± 0.04. After 1 h of initiation of NIPPV, the successful group showed improvement
regarding pH and PaCO2, while the failed group showed worsening of the same parameters, with a
signiﬁcant difference (p value <0.001, 0.005), respectively. After 4 h, there was improvement in
both groups regarding pH which reached normalization in the successful group, PaCO2, and
PO2, with no statistical signiﬁcant difference. There were signiﬁcant differences in the respiratory
rate (p value < 0.001), and the expiratory positive airway pressure (EPAP) (p value 0.024) between
the two groups. Thus we can conclude that the use of NIPPV in such patients can be successful in
around 78% of cases, however failure can be predicted by high BMI, initial lower pH and higher
PaCO2, insigniﬁcant response to NIPPV after 1 h. They also show increased respiratory rate and
need for higher expiratory positive airway pressure.
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The ﬁrst-line treatment of patients with acute respiratory
failure (ARF) is mechanical ventilation either with positive
or negative pressure, invasively or noninvasively [1]. A great
deal of clinical research has shown that non-invasive
ventilation (NIV), is a valuable form of treatment for ARF.
NIV is not yet ﬁrmly established in acute care in all institutions
[2]. Many potential advantages of non-invasive over invasive
ventilation include greater patient comfort and ease ofhe Egyptian Society of Chest Diseases and Tuberculosis.
2.018
310 M.A. Soliman et al.administration (at least in chronic settings), reduced morbidity
and mortality, and more economical administration [3].
Indications of use of NIPPV include hypercapnic ARF,
hypoxemic ARF, cardiogenic pulmonary edema, the perioper-
ative phase, early weaning and the postextubation phase, NIV
in pediatrics and palliation [2]. Although NIPPV showed great
success in the management of acute hypercapnic exacerbations
of COPD, yet there is a certain percentage of failure and those
failing patients will require invasive mechanical ventilation [4].
Rationale
Evaluation of the effectiveness of NIPPV in the management
of acute respiratory failure in COPD patients.
Methodology
This is a prospective observational study that was conducted in
the Respiratory Intensive Care Unit (RICU) Chest Depart-
ment Cairo University Hospitals. COPD patients presenting
with ARF treated by NIV in the period from May 2010 to
April 2011 had been enrolled.
All patients were subjected to full medical history and
clinical examination, radiological assessment by plain Chest
X-ray, arterial blood gases and Routine laboratory investiga-
tions such as kidney and liver function tests. Then patientsTable 1 Descriptive statistics, results of Student’s t-test and
chi-square test for comparisons between demographic data in
successful and failed groups.
Parameters Successful (n= 21) Failed (n= 6) P-value
Age (Years) 57.9 ± 8.8 62.3 ± 5 0.252
BMI (kg/m2) 28.1 ± 3.3 34 ± 3.7 0.001*
Gender (n,%)
Male 18 (85.7) 5 (83.3) 0.885
Female 3 (14.3) 1 (16.7)
* Signiﬁcant at P 6 0.05.
Table 2 Descriptive statistics and results of Student’s t-test and M
ABG in successful group and failed group.
Time ABG Successful COPD
Before NIPPV pH 7.27 ± 0.04
PaCO2 (%) 84 ± 15.5
PO2 (%) 54.5 ± 14.7
After 1 h pH 7.30 ± 0.03
PaCO2 (%) 70.2 ± 14.7
PO2 (%) 65.6 ± 24.2
After 4 h pH 7.35 ± 0.03
PaCO2 (%) 60 ± 15.3
PO2 (%) 67.8 ± 15.5
After 24 h pH 7.40 ± 0.05
PaCO2 (%) 57.1 ± 13.3
PO2 (%) 69.8 ± 14
* Signiﬁcant at P 6 0.05.were subjected to NIPPV according to the inclusion criteria
mentioned below and others who met the exclusion criteria will
be discarded.
Inclusion criteria
Patients who fulﬁll the deﬁnition of acute respiratory failure
[5]:
Clinical signs and symptoms of acute respiratory distress:
dyspnea, respiratory rate more than 24 breaths per minute,
use of accessory muscles of respiration, presence of paradoxi-
cal breathing and,
Arterial blood gas (ABG) analysis with: PH < 7.35, partial
pressure of oxygen in arterial blood (PaO2)/fraction of inspired
oxygen concentration (FiO2) ratio less than 200 (or PaO2 less
than 60 mmHg).
Exclusion criteria
These include respiratory arrest, medically unstable condition
(hypotension, uncontrolled cardiac ischemia/arrhythmia etc.),
inability to protect airway (excess secretions, stuporous or
comatose patient), abnormalities which preclude proper ﬁt of
the interface (agitated or uncooperative patient, facial trauma
or burns, facial surgery or facial anatomical abnormality).
Noninvasive ventilation will be administered by the use of
portable noninvasive ventilator (RESMED, VPAP IV). NIP-
PV will be delivered to patients in bed at an angle of 30–45
and in all patients a full face mask will be used as an interface
for delivery of positive pressure.
At the outset the patient will start on an IPAP of 8 and
EPAP of 4 cm H2O. The pressures will be gradually adjusted
as tolerated based on continuous pulse-oximetry, arterial
blood gases alleviation of patient’s dyspnea, decrease in respi-
ratory rate and good patient – ventilator synchrony.
27 COPD patients with ARF were subjected to NIPPV with
21 cases showing success (ABG improvement without a need
for invasive MV in the ﬁrst 24 h) and 6 cases showing failure
and needed invasive mechanical ventilation eventually. (These
cases were COPD with comorbidities; 2 cases were diabetic, 2ann–Whitney U test (for PaCO2 data) for comparisons between
(n= 21) Failed COPD (n= 6) P-value
7.20 ± 0.05 0.001*
85.3 ± 18.9 1.000
56.2 ± 16.6 0.813
7.19 ± 0.08 <0.001*
87.5 ± 7.3 0.005*
53.8 ± 23 0.299
7.32 ± 0.07 0.137
62.2 ± 15.7 0.559
70.3 ± 12.5 0.714
7.37 ± 0.07 0.245
55.8 ± 20.7 0.320
76.3 ± 14.3 0.323
Table 3 Descriptive statistics and results of repeated measures ANOVA test and Friedman’s test (for PaCO2 data) for comparisons
between ABG values through different time periods in successful group.
ABG Before NIPPV 1 h 4 h 24 h P-value
pH 7.27 ± 0.04c 7.30 ± 0.03c 7.35 ± 0.03b 7.40 ± 0.05a <0.001*
PaCO2 84 ± 15.5
a 70.2 ± 14.7b 60 ± 15.3c 57.1 ± 13.3c <0.001*
PaO2 54.5 ± 14.7
b 65.6 ± 24.2a 67.8 ± 15.5a 69.8 ± 14a <0.001*
Different letters in the same row are statistically signiﬁcantly different.
* Signiﬁcant at P 6 0.05.
Table 4 Descriptive statistics and results of repeated measures ANOVA test and Friedman’s test (for PaCO2 data) for comparisons
between ABG values through different time periods in failed group.
ABG Before NIPPV 1 h 4 h 24 h P-value
pH 7.20 ± 0.05b 7.19 ± 0.08b 7.32 ± 0.07a 7.37 ± 0.07a <0.001*
PaCO2 85.3 ± 18.9
a 87.5 ± 7.3a 62.2 ± 15.7b 55.8 ± 20.7b <0.001*
PO2 56.2 ± 16.6
b 53.8 ± 23b 70.3 ± 12.5a 76.3 ± 14.3a <0.001*
Different letters in the same row are statistically signiﬁcantly different.
* Signiﬁcant at P 6 0.05.
Table 5 Descriptive statistics, results of Student’s t-test,
Mann–Whitney U test (for duration) and chi-square test for
comparisons between mechanical ventilation data in successful
and failed groups.
Parameters Successful (n= 21) Failed (n= 6) P-value
Inspiratory pressure 8.8 ± 1.2 9.3 ± 1 0.294
Expiratory pressure 4.2 ± 0.4 4.7 ± 0.5 0.024*
Respiratory rate 21.1 ± 3.4 28.2 ± 2.6 <0.001*
Tidal volume 477.1 ± 51.8 478.3 ± 37.1 0.959
* Signiﬁcant at P 6 0.05.
Effectiveness of non invasive positive pressure ventilation in chronic obstructive pulmonary disease patients 311were hypertensive, 1 case had pneumonia and 1 case had con-
gestive heart failure).
Results
See Tables 1–5.
Discussion
27 COPD patients with ARF were subjected to NIPPV over a
period of 24 h 21 cases showed success and 6 cases showed fail-
ure and needed invasive mechanical ventilation. Both groups
were age and sex matched (Table 1).
The failed group showed statistically signiﬁcant (p value
0.001) higher mean BMI 34 ± 3.7 than successful COPD cases
28.1 ± 3.3. So, it was suggested that obesity may be one of the
risk factors that may cause failure of NIPPV in COPD
patients, thus considered an important risk factor for
respiratory disorders [6].
A link between obesity and/or metabolic syndrome and
COPD is increasingly recognized, however it is not fully eluci-
dated. Nevertheless, several pathogenetic mechanisms may
link these two conditions systemic inﬂammation and reduced
physical activity [7]. On one hand, airﬂow limitation limits
exercise performance and reduces physical activity, and conse-
quently increases propensity to weight gain in patients withCOPD. On the other hand, obesity further compromises pul-
monary functions contributing to patient’s inactivity [6].
Regarding systemic inﬂammation, the expression and/or
secretion of inﬂammatory molecules (proinﬂammatory adipo-
kines) are increased in the adipose tissue of obese individuals
[8], such as IL-6 [9], TNF-a and leptin [10]. This attributed
with reduced blood ﬂow per unit adipose tissue mass in obese
humans resulting in decreased blood supply to the tissues, end-
ing in relative hypoxia and increased inﬂammatory response
[11]. The signiﬁcant inverse relationships between PaO2 and
circulating TNF-a in these patients, results in increased lipid
peroxidation products, and reduced circulating antioxidative
enzymes, at rest and during exercise, and even further during
exacerbations of the disease [12].
By comparing the ABG values between the successful
group and failed group before NIPPV and after 1, 4 and
24 h as shown in Table 2, it was found that before NIPPV;
the successful group showed statistically signiﬁcantly (p value
0.001) higher mean pH 7.27 ± 0.04 than failed COPD cases
7.20 ± 0.05. Although severe respiratory acidosis <7.25 carry
a high failure rate with NIPPV, which may reach more than
50% of cases in some studies [13], trying NIPPV may still be
justiﬁed, even in the presence of hypercapnic encephalopathy,
as long as no other indications for invasive support and facil-
ities for prompt endotracheal intubation are available [13].
After 1 h of NIPPV; the successful group cases showed sta-
tistically signiﬁcantly higher mean pH 7.30 ± 0.03, lower CO2
level 70.2 ± 14.7 than the failed group with lower pH
7.19 ± 0.08 and higher PCO2 level 87.5 ± 7.3. This means
that the etiology of ARF, severity of acidemia and the degree
of hypercapnea may be predictive factors for the success of
NIPPV in COPD cases especially in the 1st hour after NIPPV
and this is in agreement with ﬁndings of Agarawal et al. [5] and
in disagreement with the ﬁndings of Poponick et al. [14].
The ABG values of the successful group (Table 3) showed
that there were signiﬁcant improvement of the pH, PCO2
and PO2 over the 1st, 4th, and 24th hours of NIPPV. This
means that the correction of hypoxemia and hypercapnea
was the earliest change followed by the correction of PH in
the 1st hour after NIPPV and therefore these variables can
312 M.A. Soliman et al.be used as predictive factors for success of NIPPV as men-
tioned before. This was conﬁrmed by the ﬁndings of the failed
group (Table 4), where there were no signiﬁcant differences in
the same parameters in the 1st hour of NIPPV. Signiﬁcant
changes occurred after 4 h, however the condition ended by
failure of NIPPV and shift to invasive MV. Anton et al. [15]
suggested that if NIPPV does not improve pH and RR within
the ﬁrst two hours, intubation should be considered.
Moreover the concomitant medical condition of the
patients as found in the current study should be taken into
consideration. All the cases that showed failure with NIPPV
had comorbidities as diabetes, hypertension, pneumonia and
congestive heart failure. This was in agreement with many
studies, which stated that NIPPV failure was greater in
patients with medical comorbidities either acute or chronic
[16–18], especially cardiovascular diseases [19] and pneumonia
[17]. This may be due to the associated refractory hypoxemia
and hypoxemic respiratory failure [20]. However in diabetes,
there is also affection of the peripheral airways and impaired
compliance [21].
The failed group needed higher levels of expiratory pres-
sures (Table 5) in order to overcome the severe obstruction
which was augmented by the presence of high autoPEEP
[22]. Respiratory rate at admission was signiﬁcantly higher in
the NIPPV failed group as compared with the NIPPV success-
ful group, and this could possibly be used to predict response
to NIPPV [23,24].Conclusion
The use of NIPPV in acute hypercapnic respiratory failure due
to COPD showed great success (around 78% of cases), how-
ever certain patients fail and still require invasive mechanical
ventilation. Failure can be predicted by high BMI, initial lower
pH and higher PaCO2 and insigniﬁcant response to NIPPV
after 1 h. They also show increased respiratory rate and need
for higher expiratory positive airway pressure.Conﬂict of interest
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